Trial · NCT05052801
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival | Up to approximately 3.5 years | Overall survival in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Progression-free Survival (PFS) | Up to approximately 3.5 years | PFS in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Objective Response Rate (ORR) | Up to approximately 3.5 years | ORR in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Number of Participants who Experience a Treatment-emergent Adverse Event (TEAE) | Up to approximately 3.5 years | Any clinically significant changes in vital signs, visual acuity, and clinical laboratory tests after first dose will be recorded as TEAEs. |
| Secondary | Overall Survival | Up to approximately 3.5 years | Overall survival in all randomized participants |
| Secondary | Progression-free Survival (PFS) | Up to approximately 3.5 years | PFS in all randomized participants |
| Secondary | Objective Response Rate (ORR) | Up to approximately 3.5 years | ORR in all randomized participants |
| Secondary | Duration of Response (DOR) | Up to approximately 3.5 years | DOR in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Disease Control Rate | Up to approximately 3.5 years | Disease Control Rate in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Mean Subjective Score in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) | Up to approximately 3.5 years | Measured in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Change from Baseline Score in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) | Baseline up to approximately 3.5 years | Measured in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Stomach Cancer Related Symptom Mean Subjective Score as Measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Stomach (EORTC-QLQ-STO22) | Up to approximately 3.5 years | Measured in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Change from Baseline in Stomach Cancer Related Symptom Score as Measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Stomach (EORTC-QLQ-STO22) | Baseline up to approximately 3.5 years | Measured in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Mean Subjective Score in Visual Analogue Scale (VAS) as Measured by the EuroQol 5-dimensional 5-levels (EQ-5D-5L) | Up to approximately 3.5 years | Measured in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Change from Baseline of Visual Analogue Scale (VAS) as Measured by the EuroQol 5-dimensional 5-levels (EQ-5D-5L) | Baseline up to approximately 3.5 years | Measured in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Time to Deterioration in Stomach Cancer Related Symptom Score as Measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Stomach (EORTC-QLQ-STO22) | Up to approximately 3.5 years | Measured in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Time to Deterioration in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) Score | Up to approximately 3.5 years | Measured in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Time to Deterioration in Visual Analogue Scale (VAS) as Measured by the EuroQol 5-dimensional 5-levels (EQ-5D-5L) Score | Up to approximately 3.5 years | Measured in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Time to Deterioration in Physical Function Score as Measured by a Subscale of European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) | Day 1 up to approximately 3.5 years | Measured in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Maximum Observed Concentration (Cmax) of Bemarituzumab in Combination with mFOLFOX6 in Plasma | Day 1 up to approximately 3.5 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05052801/registered